AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12810617 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous ultrasound method for evaluating elasticity of atherosclerotic plaque
Number of subjects: 0
Study 12810617 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous ultrasound method
Number of subjects: 0
Study 10671820 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled, stimulated cycles (n = 33)
Number of subjects: 46
Study 10671820 — intervention group
Group type: COMPARATOR
Intervention: Normal menstrual cycles (n = 13)
Number of subjects: 46
Study 10671820 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 46
Study 8892713 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 875
Study 8892713 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens (CEE), 0.625 mg/d
Number of subjects: 875
Study 8892713 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE plus medroxyprogesterone acetate (MPA), 10 mg/d for 12 d/mo
Number of subjects: 875
Study 8892713 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE plus MPA, 2.5 mg/d daily
Number of subjects: 875
Study 8892713 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE plus micronized progesterone (MP), 200 mg/d for 12 d/mo
Number of subjects: 875
Study 1855298 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-generation fructosamine assay
Number of subjects: 529
Study 1855298 — intervention group
Group type: EXPERIMENTAL
Intervention: First-generation fructosamine assay
Number of subjects: 529
Study 6681024 — intervention group
Group type: EXPERIMENTAL
Intervention: Minoxidil (5-40 mg/day)
Number of subjects: 36
Study 6681024 — intervention group
Group type: COMPARATOR
Intervention: Hydralazine (25-200 mg/day)
Number of subjects: 36
Study 6681024 — intervention group
Group type: COMPARATOR
Intervention: Hydralazine
Number of subjects: 36
Study 6681024 — intervention group
Group type: EXPERIMENTAL
Intervention: Minoxidil
Number of subjects: 36
Study 30623821 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-focused therapy (FFT-A)
Number of subjects: 145
Study 30623821 — intervention group
Group type: COMPARATOR
Intervention: Enhanced care (EC)
Number of subjects: 145
Study 30623821 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbid anxiety disorders
Number of subjects: 145
Study 30623821 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbid ADHD
Number of subjects: 145
Study 30623821 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbid DBDs
Number of subjects: 145
Study 30149272 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS)
Number of subjects: 0
Study 30149272 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0
Study 28269582 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive abduction loading therapy
Number of subjects: 31
Study 25040338 — intervention group
Group type: EXPERIMENTAL
Intervention: Women's Health CoOp (WHC)
Number of subjects: 84
Study 25040338 — intervention group
Group type: COMPARATOR
Intervention: Comparison arms
Number of subjects: 84
Study 22157929 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine with midazolam premedication
Number of subjects: 201
Study 22157929 — intervention group
Group type: COMPARATOR
Intervention: Ketamine without midazolam premedication
Number of subjects: 201
Study 21042013 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sodium bicarbonate (increasing dose until serum total CO(2) ≥ 24 mM)
Number of subjects: 0
Study 21042013 — intervention group
Group type: COMPARATOR
Intervention: Control group (same medications, no sodium bicarbonate)
Number of subjects: 0
Study 16697413 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline with transdermal estrogen (ET)
Number of subjects: 22
Study 16697413 — intervention group
Group type: COMPARATOR
Intervention: Sertraline with placebo
Number of subjects: 22
Study 15908297 — intervention group
Group type: EXPERIMENTAL
Intervention: Thin petrolatum
Number of subjects: 31
Study 15908297 — intervention group
Group type: EXPERIMENTAL
Intervention: Thick petrolatum
Number of subjects: 31
Study 15908297 — intervention group
Group type: EXPERIMENTAL
Intervention: Thin 20% salicylic acid in petrolatum
Number of subjects: 31
Study 15908297 — intervention group
Group type: EXPERIMENTAL
Intervention: Thick 20% salicylic acid in petrolatum
Number of subjects: 31
Study 15908297 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunscreen
Number of subjects: 31
Study 12910199 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazide diuretics
Number of subjects: 90
Study 12910199 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive drugs
Number of subjects: 90
Study 10235440 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.1 g n-3 FA daily for 6 months
Number of subjects: 23
Study 10235440 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g n-3 FA daily for another 4 weeks (after initial treatment)
Number of subjects: 23
Study 10235440 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group II)
Number of subjects: 23
Study 8606810 — intervention group
Group type: EXPERIMENTAL
Intervention: PCR amplification using radioactive deoxynucleotides
Number of subjects: 100
Study 8606810 — intervention group
Group type: EXPERIMENTAL
Intervention: PCR amplification using fluorescent oligonucleotide primers
Number of subjects: 100
Study 8606810 — intervention group
Group type: COMPARATOR
Intervention: Comparison of radioactive and fluorescent assays
Number of subjects: 100
Study 8606810 — intervention group
Group type: EXPERIMENTAL
Intervention: Reporting and counselling procedures for presymptomatic testing
Number of subjects: 100
Study 1720483 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 20
Study 1720483 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 20
Study 1720483 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 20
Study 7022037 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine alone
Number of subjects: 20
Study 7022037 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine and glucagon combination
Number of subjects: 20
Study 7022037 — intervention group
Group type: COMPARATOR
Intervention: Nasogastric suction
Number of subjects: 20
Study 31389157 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg daily oral modified release morphine
Number of subjects: 45
Study 31389157 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 29494866 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Number of subjects: 30
Study 29494866 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducational (PE)
Number of subjects: 30
Study 26991683 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurses who reported being 'somewhat comfortable' discussing CAM
Number of subjects: 699
Study 26991683 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurses who reported being 'very comfortable' discussing CAM
Number of subjects: 699
Study 26991683 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurses who self-reported use of massage
Number of subjects: 699
Study 26991683 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurses with formal CAM education
Number of subjects: 699
Study 26991683 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurses who reported being 'somewhat comfortable' referring patients to CAM therapies
Number of subjects: 699
Study 26991683 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurses who reported being 'very comfortable' referring patients to CAM therapies
Number of subjects: 699
Study 26991683 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurses with formal CAM education referring patients to CAM therapies
Number of subjects: 699
Study 24876156 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT) with EMG biofeedback and sham neuromuscular electrostimulation (NMES)
Number of subjects: 30
Study 24876156 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT) with EMG biofeedback and intravaginal NMES
Number of subjects: 30
Study 24876156 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT) with EMG biofeedback and transcutaneous tibial nerve stimulation (TTNS)
Number of subjects: 30
Study 22844698 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sodium diet (0.34 g/kg)
Number of subjects: 3
Study 22844698 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium sodium diet (1.34 g/kg)
Number of subjects: 3
Study 22844698 — intervention group
Group type: EXPERIMENTAL
Intervention: High sodium diet (2.82 g/kg)
Number of subjects: 3
Study 19602953 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia (combination of one of four hypnotic drugs supplemented by one of four opioids)
Number of subjects: 156
Study 19602953 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia
Number of subjects: 156
Study 17610727 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol/fluticasone propionate (SAL/FP) 50/250 mug BID
Number of subjects: 688
Study 17610727 — intervention group
Group type: COMPARATOR
Intervention: Formoterol/budesonide (FOR/BUD) 6/200 mug BID
Number of subjects: 688
Study 15269071 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Number of subjects: 800
Study 15269071 — intervention group
Group type: COMPARATOR
Intervention: No influenza vaccine (Control)
Number of subjects: 800
Study 12477513 — intervention group
Group type: EXPERIMENTAL
Intervention: Carnitines (group A; n = 30) for 4 months
Number of subjects: 98
Study 12477513 — intervention group
Group type: COMPARATOR
Intervention: Nonsteroidal anti-inflammatory drugs (group B; n = 16) for 4 months
Number of subjects: 98
Study 12477513 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsteroidal anti-inflammatory drugs for 2 months, followed by carnitines for 2 months (group C; n = 26)
Number of subjects: 98
Study 12477513 — intervention group
Group type: COMPARATOR
Intervention: Nonsteroidal anti-inflammatory treatment given concomitantly with carnitines (group D; n = 26) for 4 months
Number of subjects: 98
Study 9822455 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg of the ACE inhibitor enalaprilat
Number of subjects: 8
Study 9822455 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 7663641 — intervention group
Group type: EXPERIMENTAL
Intervention: Sway speed with eyes open (natural logarithm)
Number of subjects: 265
Study 7663641 — intervention group
Group type: EXPERIMENTAL
Intervention: Sway speed with eyes closed (natural logarithm)
Number of subjects: 265
Study 2696937 — intervention group
Group type: EXPERIMENTAL
Intervention: proxibarbal (Ipronal "Polfa") 50 mg tablets, administered one tablet twice daily for 6 weeks every quarter over 3 years
Number of subjects: 62
Study 2696937 — intervention group
Group type: COMPARATOR
Intervention: placebo tablets, administered one tablet twice daily for 6 weeks every quarter over 3 years
Number of subjects: 62
Study 798626 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 10 mg bid
Number of subjects: 74
Study 798626 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 15 mg/m2 bid
Number of subjects: 74
Study 798626 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (both dosages)
Number of subjects: 74
Study 31565750 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine (IIV3)
Number of subjects: 285
Study 31565750 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 285
Study 29114517 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprioceptive neuromuscular facilitation-based abdominal muscle strengthening training (PNF-AMST)
Number of subjects: 30
Study 29114517 — intervention group
Group type: COMPARATOR
Intervention: Traditional physical therapy (control)
Number of subjects: 30
Study 24778425 — intervention group
Group type: EXPERIMENTAL
Intervention: Clot strength
Number of subjects: 40
Study 24778425 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet aggregation
Number of subjects: 40
Study 23550791 — intervention group
Group type: EXPERIMENTAL
Intervention: GuardianCPV
Number of subjects: 120
Study 23550791 — intervention group
Group type: COMPARATOR
Intervention: LMA Supreme
Number of subjects: 120
Study 23804793 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n = 31)
Number of subjects: 55
Study 23804793 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 24)
Number of subjects: 55
Study 18990678 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (low-dose inhaled corticosteroid)
Number of subjects: 7165
Study 18990678 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7165
Study 18990678 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide vs Placebo
Number of subjects: 7165
Study 18990678 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 7165
Study 16942947 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional Pain Coping Skills Training (PCST)
Number of subjects: 167
Study 16942947 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain Coping Skills Training with Maintenance Training (PCST/MT)
Number of subjects: 167
Study 16942947 — intervention group
Group type: COMPARATOR
Intervention: Arthritis Education Control
Number of subjects: 167
Study 16942947 — intervention group
Group type: COMPARATOR
Intervention: Standard Care Control
Number of subjects: 167
Study 14986244 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous and oral clinafloxacin treatment for native valve infection
Number of subjects: 66
Study 14986244 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous and oral clinafloxacin treatment for prosthetic valve endocarditis (PVE)
Number of subjects: 66
Study 11380230 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined chemotherapy and radiotherapy (CRT)
Number of subjects: 70
Study 11380230 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (RT)
Number of subjects: 70
Study 11380230 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined chemotherapy and radiotherapy (CRT) after radical resection
Number of subjects: 70
Study 11380230 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (RT) after radical resection
Number of subjects: 70
Study 9222074 — intervention group
Group type: EXPERIMENTAL
Intervention: Alatrofloxacin 30 mg
Number of subjects: 15
Study 9222074 — intervention group
Group type: EXPERIMENTAL
Intervention: Alatrofloxacin 100 mg
Number of subjects: 15
Study 9222074 — intervention group
Group type: EXPERIMENTAL
Intervention: Alatrofloxacin 200 mg
Number of subjects: 15
Study 9222074 — intervention group
Group type: EXPERIMENTAL
Intervention: Alatrofloxacin 300 mg
Number of subjects: 15
Study 9222074 — intervention group
Group type: EXPERIMENTAL
Intervention: Alatrofloxacin (all doses)
Number of subjects: 15
Study 8107184 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg)
Number of subjects: 18
Study 8107184 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide-5-mononitrate (60 mg)
Number of subjects: 18
Study 8107184 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 18
Study 3663551 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (150 mg) alone
Number of subjects: 68
Study 3663551 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate in combination with human menopausal gonadotrophins (hMG)
Number of subjects: 68
Study 3663551 — intervention group
Group type: EXPERIMENTAL
Intervention: hMG alone
Number of subjects: 68
Study 3663551 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene in combination with hMG
Number of subjects: 68
Study 31259600 — intervention group
Group type: EXPERIMENTAL
Intervention: Holistic processing
Number of subjects: 0
Study 31259600 — intervention group
Group type: COMPARATOR
Intervention: Relational representations
Number of subjects: 0
Study 28467262 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: 3 × 12 minutes for two sessions
Number of subjects: 30
Study 28467262 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B: 1 × 36 minutes over two sessions
Number of subjects: 30
Study 28467262 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 30
Study 26695486 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg testosterone undecanoate (Nebido(®))
Number of subjects: 6
Study 26695486 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg testosterone propionate, 60 mg testosterone phenylpropionate, 60 mg testosterone isocaproate, and 100 mg testosterone decanoate (Sustanon(®))
Number of subjects: 6
Study 26695486 — intervention group
Group type: COMPARATOR
Intervention: Blood collection devices (stabilizing additives vs non‐stabilized serum separation tubes)
Number of subjects: 6
Study 23968788 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week Tier 1 Response to Intervention (RtI) program
Number of subjects: 113
Study 23968788 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 113
Study 23968788 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 113
Study 21674594 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental OAB drug
Number of subjects: 58
Study 21674594 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 18269429 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial intervention (5-week programme and 3-month conversation group)
Number of subjects: 308
Study 18269429 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 308
Study 16646405 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 337
Study 16646405 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 337
Study 15066366 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle Education for Activity Program (LEAP) - a comprehensive school-based intervention emphasizing changes in instruction and school environment.
Number of subjects: 2087
Study 15066366 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 2087
Study 15066366 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle Education for Activity Program (LEAP).
Number of subjects: 2087
Study 11069725 — intervention group
Group type: EXPERIMENTAL
Intervention: Full irrigation with 3000 ml of saline
Number of subjects: 90
Study 11069725 — intervention group
Group type: COMPARATOR
Intervention: Minimal irrigation with 250 ml saline
Number of subjects: 90
Study 9312318 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide
Number of subjects: 2
Study 9312318 — intervention group
Group type: COMPARATOR
Intervention: Sodium chloride solution 0.9%
Number of subjects: 2
Study 9312318 — intervention group
Group type: COMPARATOR
Intervention: Oxybuprocaine 0.4%
Number of subjects: 2
Study 8467542 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: 2 ml bolus/10 min lockout interval
Number of subjects: 68
Study 8467542 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B: 3 ml bolus/15 min lockout interval
Number of subjects: 68
Study 8467542 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C: 4 ml bolus/20 min lockout interval
Number of subjects: 68
Study 8467542 — intervention group
Group type: EXPERIMENTAL
Intervention: Group D: 6 ml bolus/30 min lockout interval
Number of subjects: 68
Study 8467542 — intervention group
Group type: EXPERIMENTAL
Intervention: Group E: 8 ml/hr continuous infusion
Number of subjects: 68
Study 3468737 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG biofeedback treatment (8 sessions, twice a week for 4 weeks)
Number of subjects: 0
Study 3468737 — intervention group
Group type: COMPARATOR
Intervention: Control group (no EMG biofeedback)
Number of subjects: 0
Study 3468737 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (EXP and CON)
Number of subjects: 0
Study 3468737 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective clinical indices
Number of subjects: 0
Study 30389092 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated PFI (computer-based personalized feedback intervention)
Number of subjects: 68
Study 30389092 — intervention group
Group type: COMPARATOR
Intervention: Control PFI
Number of subjects: 68
Study 30390654 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of prophylaxis
Number of subjects: 260
Study 30390654 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of stay in a highly endemic region
Number of subjects: 260
Study 30390654 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency of travel
Number of subjects: 260
Study 30390654 — intervention group
Group type: COMPARATOR
Intervention: Imported cases classification
Number of subjects: 260
Study 26815248 — intervention group
Group type: EXPERIMENTAL
Intervention: C‐PEN
Number of subjects: 80
Study 26815248 — intervention group
Group type: COMPARATOR
Intervention: C‐ESI
Number of subjects: 80
Study 25491033 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flux polysulfone membrane (Helixone®)
Number of subjects: 90
Study 25491033 — intervention group
Group type: COMPARATOR
Intervention: Low-flux polysulfone membrane
Number of subjects: 90
Study 21896558 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal facilitation tool
Number of subjects: 205
Study 21896558 — intervention group
Group type: COMPARATOR
Intervention: Standard needs assessment (Control)
Number of subjects: 205
Study 21151493 — intervention group
Group type: EXPERIMENTAL
Intervention: RS4
Number of subjects: 10
Study 21151493 — intervention group
Group type: EXPERIMENTAL
Intervention: RS2
Number of subjects: 10
Study 21151493 — intervention group
Group type: COMPARATOR
Intervention: Native starch (control)
Number of subjects: 10
Study 17604178 — intervention group
Group type: EXPERIMENTAL
Intervention: Celsior
Number of subjects: 60
Study 17604178 — intervention group
Group type: COMPARATOR
Intervention: St. Thomas No. 2
Number of subjects: 60
Study 16085678 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients (n=7)
Number of subjects: 12
Study 16085678 — intervention group
Group type: COMPARATOR
Intervention: Control patients (n=5)
Number of subjects: 12
Study 11866264 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-H. pylori therapy
Number of subjects: 48
Study 11866264 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorambucil p.o. for 6 months
Number of subjects: 48
Study 11866264 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorambucil p.o. for 1 year
Number of subjects: 48